Bioventus (BVS) vs Sight Sciences (SGHT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sight Sciences (SGHT) has outperformed Bioventus (BVS) over the past year, gaining 40.2% versus a gain of 36.5%. Over five years, BVS leads with a -21.0% price change compared with -46.7% for SGHT. Bioventus is the larger company by market cap ($676.5 million vs $565.8 million), about 1.2 times the size.
Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -49.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | SGHT |
|---|---|---|
| Share price | $9.88 | $10.18 |
| Market cap | $676.53M | $565.79M |
| 1-day change | -0.70% | -4.14% |
| YTD return | +32.80% | +28.37% |
| 1-year return | +36.46% | +40.22% |
| 5-year return | -21.02% | -46.67% |
| P/E ratio (TTM) | 12.20 | — |
| Forward P/E | 11.13 | — |
| EPS (TTM) | $0.81 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $568.09M | $77.36M |
| Revenue growth (YoY) | -0.91% | -3.13% |
| Net income (latest FY) | $22.73M | $-38.43M |
| Gross margin | 68.33% | 86.17% |
| Operating margin | 9.50% | -47.95% |
| Net margin | 4.00% | -49.67% |
| 52-week high | $15.89 | $11.60 |
| 52-week low | $7.02 | $3.38 |
| Distance from 52-week high | -37.83% | -12.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +68.02% | +20.33% |
| Average volume | 536.81K | 313.51K |
| Shares outstanding | 68.47M | 55.58M |
| Employees | 960 | 186 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -49.7 cents for Sight Sciences.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 960 employees
About Sight Sciences
SGHT stock →Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Health Care · Medical/Dental Instruments · 186 employees
BVS vs SGHT FAQ
Which is bigger, Bioventus or Sight Sciences?
Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $565.79M for Sight Sciences (SGHT).
Which stock has performed better over the past year, BVS or SGHT?
SGHT returned +40.22% over the past 12 months, compared with +36.46% for BVS (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and Sight Sciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.